 India's leading drugmaker Ranbaxy Laboratories suffered a setback last week when US Food and Drug Administration imposed "import alert" on its Mohali plant after a black fibre, suspected to be a hair, was found embedded in a tablet. With more than 40% sales from US, it is a blow to an Indian generic-drug industry.